CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 204 enrolled
Drug / intervention
acetylsalicylic aciddrug
Likely dose
acetylsalicylic acid 325mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00872534
NCT00872534Phase 2Completed
CompareCT.gov

A Randomized, Single-Blind, Endoscopic Evaluation Of Upper GI Mucosal Damage Induced By PL-2200 Versus Aspirin In Healthy Volunteers

PLx Pharma·interventional·Posted Mar 31, 2009·Updated Aug 11, 2015

In Brief

A Phase 2 clinical trial evaluating acetylsalicylic acid for Upper Gastrointestinal Mucosal Damage. Completed, enrolled 204 participants across 6 sites.

Detailed Summary

To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUpper Gastrointestinal Mucosal Damage
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 31, 2009
Enrollment StartJan 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.3 years ago

Interventions

acetylsalicylic aciddrug

325mg once a day for 7 days